ADMA Relative Valuation
ADMA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ADMA is overvalued; if below, it's undervalued.
Historical Valuation
ADMA Biologics Inc (ADMA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.09 is considered Undervalued compared with the five-year average of -1.74. The fair price of ADMA Biologics Inc (ADMA) is between 25.75 to 34.63 according to relative valuation methord. Compared to the current price of 17.88 USD , ADMA Biologics Inc is Undervalued By 30.57%.
Relative Value
Fair Zone
25.75-34.63
Current Price：17.88
30.57%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
11.43
P/B
Median3y
9.97
Median5y
6.90
2.08
FCF Yield
Median3y
-4.57
Median5y
-23.25
Competitors Valuation Multiple
The average P/S ratio for ADMA's competitors is 44.77, providing a benchmark for relative valuation. ADMA Biologics Inc Corp (ADMA) exhibits a P/S ratio of 8.09, which is -81.94% above the industry average. Given its robust revenue growth of 40.22%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is ADMA Biologics Inc (ADMA) currently overvalued or undervalued?
What is ADMA Biologics Inc (ADMA) fair value?
How does ADMA's valuation metrics compare to the industry average?
What is the current P/B ratio for ADMA Biologics Inc (ADMA) as of Jul 08 2025?
What is the current FCF Yield for ADMA Biologics Inc (ADMA) as of Jul 08 2025?
What is the current Forward P/E ratio for ADMA Biologics Inc (ADMA) as of Jul 08 2025?